CEQUENT PHARMACEUTICALS

cequent-pharmaceuticals-logo

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases รขโ‚ฌโ€œ from inflammatory diseases to cancer รขโ‚ฌโ€œ based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deac... tivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.

#SimilarOrganizations #People #Financial #Website #More

CEQUENT PHARMACEUTICALS

Industry:
Biotechnology Health Care Therapeutics

Founded:
2006-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.cequentpharma.com

Total Employee:
11+

Status:
Active

Contact:
617-995-7940

Email Addresses:
[email protected]

Total Funding:
12.4 M USD

Technology used in webpage:
SPF Domain Not Resolving OVH


Similar Organizations

vigeo-therapeutics-logo

Vigeo Therapeutics

Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.

Current Employees Featured

johannes-fruehauf_image

Johannes Fruehauf
Johannes Fruehauf Co-Founder @ Cequent Pharmaceuticals
Co-Founder

Founder


johannes-fruehauf_image

Johannes Fruehauf

Investors List

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series A - Cequent Pharmaceuticals

nexus-medical-partners_image

Nexus Medical Partners

Nexus Medical Partners investment in Series A - Cequent Pharmaceuticals

ampersand-ventures_image

Ampersand Capital Partners

Ampersand Capital Partners investment in Series A - Cequent Pharmaceuticals

pappas-ventures_image

Pappas Ventures

Pappas Ventures investment in Series A - Cequent Pharmaceuticals

Official Site Inspections

http://www.cequentpharma.com

  • Host name: ip79.ip-144-217-233.net
  • IP address: 144.217.233.79
  • Location: Beauharnois Canada
  • Latitude: 45.3161
  • Longitude: -73.8736
  • Timezone: America/Toronto
  • Postal: J6N

Loading ...

More informations about "Cequent Pharmaceuticals"

Cequent Pharmaceuticals - Prevent and Treat a Wide Range of โ€ฆ

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases from inflammatory diseases โ€ฆSee details»

Company | Cequent Pharma

About Cequent Pharmaceuticals, Inc. An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human โ€ฆSee details»

Cequent Pharmaceuticals - Crunchbase Company โ€ฆ

Contact Email [email protected] Phone Number 617-995-7940 An early-stage biopharmaceutical company, Cequent is pioneering the development of โ€ฆSee details»

Board of Directors - Cequent Pharma

Joining Peter D. Parker on the Cequent Pharmaceuticals, Inc. Board of Directors are: Chiang J. Li, M.D. Founder, Director and Chairman of Scientific Advisory BoardSee details»

Cequent Pharmaceuticals Company Profile | Management and

Cequent Pharmaceuticals Profile and History . Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders -- from inflammatory โ€ฆSee details»

Cequent Pharmaceutials Inc., Peter D. Parker,

[email protected]: Phone: 1-617-995-7940: Website: www.cequentpharma.com Fax: 1-617-995-7941: Summary ; Executive Details ; Board Members ; Business Information The โ€ฆSee details»

Cequent Pharmaceuticals - Ownership and Business Overview

Www.cequentpharma.com. Profile Investors (2) Analytics Developer of therapies based on RNA interference (RNAi) Company Summary. SECTOR. Life Science. Established. 2003. Investor โ€ฆSee details»

Cequent Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...

Explore Cequent Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»

Cequent Pharmaceuticals - PitchBook

Cequent Pharmaceuticals General Information Description. Developer of RNAi-based therapies based in Cambridge, Massachusetts. The company focuses on biopharmaceutical products based on RNA interference to prevent and treat a โ€ฆSee details»

Cequent Pharmaceuticals - Products, Competitors, Financials, โ€ฆ

May 18, 2016 Headquarters Location. One Kendall Square Building 700 First Floor. Cambridge, Massachusetts, 02139, United States. 617-995-7940See details»

Management Team - Cequent Pharma

Peter D. Parker President and CEO. Mr. Parker is President and CEO of Cequent Pharmaceuticals, Inc. Prior to joining Cequent, Mr. Parker was a General Partner at โ€ฆSee details»

Cequent Pharmaceuticals Management Team | Org Chart

Get contact details including emails and phone numbers (business & personal).See details»

Peter Parker Cequent Pharmaceuticals Chief Executive Officer Profile

Www.cequentpharma.com: Company Description : Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on โ€ฆSee details»

Cequent Pharmaceuticals. | (617) 995-7943 | Cambridge ... - AllBiz

Alison Silva is the primary contact at Cequent Pharmaceuticals.. You can contact Cequent Pharmaceuticals. by phone using number (617) 995-7943.See details»

Cequent Names Ted Hibben Chief Business Officer

Jan 12, 2009 Regarding Mr. Hibben's role at Cequent, Mr. Parker said, "Ted will focus on external partnering activities in three major areas. On our inflammatory bowel disease (IBD) โ€ฆSee details»

Cequent Pharmaceuticals, Inc. Names F. Stephen Laroux, Ph.D

Jun 2, 2009 About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com) An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to โ€ฆSee details»

Our Partners | Cequent Pharma

The Novartis Institutes for BioMedical Research (NIBR) is Novartis global research organization. Informed by clinical insights from their translational medicine team, NIBR uses modern science โ€ฆSee details»

Pamela Fekete Cequent Pharmaceuticals VP - Regulatory Affairs โ€ฆ

Www.cequentpharma.com: Company Description : Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on โ€ฆSee details»

Scientific Team - Cequent Pharma

Johannes Fruehauf, M.D. Vice President, Research Dr. Fruehauf is VP, Research at Cequent Pharmaceuticals, Inc. and co-inventor of transkingdom RNAi (tkRNAi).See details»

Clariant announces simplified organizational and leadership โ€ฆ

Now is the right time to align the organization more closely to customers, businesses and markets. The new setup will further strengthen our position as a leader in sustainability and โ€ฆSee details»

linkstock.net © 2022. All rights reserved